Granules India has announced its acquisition of Senn Chemicals AG, a Switzerland-based Contract Development and Manufacturing Organization (CDMO) specializing in peptide synthesis.

The acquisition marks a significant milestone in Granules India’s expansion into the high-growth peptide-based therapeutics segment, including anti-diabetic and anti-obesity treatments. The deal is expected to be completed in the first half of 2025, subject to regulatory approvals and closing conditions.

Senn Chemicals AG brings advanced expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with an established customer base in pharmaceuticals, cosmetics, and theragnostic industries. Its state-of-the-art manufacturing facility is ISO 9001:2015 certified and adheres to current Good Manufacturing Practices (cGMP). The facility is regularly inspected and approved by Swissmedic, Switzerland's health regulatory authority. Under the Mutual Recognition Agreement (MRA) between Swissmedic and the U.S. Food and Drug Administration (FDA), Swissmedic’s cGMP inspections are recognized by the FDA, ensuring compliance with global regulatory standards.

This acquisition significantly strengthens Granules India’s presence in the peptide therapeutics market, particularly in the development of GLP-1 receptor agonists, a rapidly growing segment in diabetes and obesity treatment. Additionally, it enhances Granules' CDMO business, leveraging Senn’s European presence and expertise. The deal also provides access to a highly skilled R&D talent pool and key clients in regulated markets, further solidifying Granules India’s global footprint.

The integration of Senn’s capabilities with Granules' cost-effective, large-scale manufacturing expertise is expected to position Granules India as a major player in the development and manufacturing of peptide-based solutions. The company aims to offer end-to-end services, covering the entire peptide value chain from Amino Acid Derivatives (AADs) and peptide fragments to full-scale peptide-based active ingredients.

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, stated that the acquisition is a pivotal moment in the company’s strategic growth journey. By entering the rapidly expanding peptide therapeutics sector and enhancing CDMO capabilities, Granules India is furthering its commitment to innovation and affordability. He emphasized that Senn’s expertise in peptide synthesis, combined with Granules’ large-scale, cost-efficient manufacturing capabilities, will allow the company to deliver high-quality peptide-based solutions worldwide.

Echoing this sentiment, Dr. Rico Wiedenbruch, Chairman of Senn Chemicals AG, expressed enthusiasm about the partnership, highlighting the strategic alignment between the two companies. He noted that Granules India’s scale, operational efficiency, and global reach in the pharmaceutical industry would complement Senn’s expertise in peptide development and manufacturing, accelerating growth in next-generation peptide therapeutics.

The acquisition is expected to bring significant value to both companies, positioning Granules India as a key player in the evolving peptide-based therapeutics and CDMO industry. With Senn’s established European presence and innovation-driven peptide platform, Granules is set to expand its global presence and meet the growing demand for peptide-based medicines and Amino Acid Derivatives (AADs).